Windtree Therapeutics Inc (WINT)

[Monksdream]

WINT new 52 lo

[Monksdream]

WINT new 52 week low

[Mr. Zen]

Warrington-based Windtree Therapeutics is currently exploring strategic alternatives to enhance shareholder value, including the possibility of acquisitions or being acquired, writes John George for the Philadelphia Business Journal.

The company has enlisted the services of Ladenburg Thalmann & Co. Inc. to assess its options.

Despite a challenging financial landscape, Windtree has taken significant steps to bolster its financial standing. These include a lucrative licensing agreement potentially worth over $138 million and the elimination of a $15 million contingent liability.

[Monksdream]

WINT new 52 week low

[Monksdream]

WINT new 52 week low

[Mr. Zen]

NEWS:: Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced it has entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (“Lee’s”) for the development and commercialization of Windtree’s product candidate istaroxime in Greater China, including for acute heart failure and cardiogenic shock. In addition to istaroxime, the agreement also licenses Windtree’s preclinical next-generation SERCA2a activators, known as dual mechanism SERCA2a activators, and rostafuroxin, a Phase 2 product candidate for hypertension associated with specific genotypes.

[TIMGZ]

DILUTION YESTERDAY ANNOUNCED AND TODAY****MIGHT DEEP FURTHER BUT WATCHLIST FOR SURE****IT IS COMING HUGE WITH TIME

[TheFinalCD]

cold WINT rrrrr

#riskyjoke

[Monksdream]

WINT new 52 week low

[Mr. Zen]

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that the Company recently enrolled the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock. Study results are expected in mid-2024.

Building upon the positive SEISMiC study results, the Extension Study is expected to enroll up to 30 subjects with the objective to evaluate a longer dosing cycle of istaroxime, a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure. The study of hospitalized patients with early cardiogenic shock (SCAI Stage B) due to acute heart failure (AHF) will evaluate two dose regimens of istaroxime compared to placebo. Subjects on istaroxime will receive infusions for up to 60 hours with one istaroxime group receiving a tapered decreasing dose over time and the second istaroxime group receiving a consistent lower dose. In the previous SEISMiC study in early cardiogenic shock, patients were infused with drug or placebo for 24 hours. We believe extending the dosing duration of istaroxime has the potential to provide additional benefit and, along with dose titration, is an important factor in determining the optimal dosing regimen to study in a potential Phase 3 trial. The Extension Study will also gather data to characterize the potential benefits of SERCA2a activation in these patients, advancing the Company’s clinical and regulatory position for potential Phase 3 readiness.

The Company is also progressing the start-up of a parallel study in more severe, SCAI Stage C cardiogenic shock patients. SCAI Stage C patients have low blood pressure and inadequate blood flow to vital organs. The istaroxime cardiogenic shock SCAI Stage C study is expected to enroll up to 20 subjects with SCAI Stage C cardiogenic shock due to AHF. Multiple physiologic measures associated with cardiac function, blood pressure and safety will be assessed. The Company is targeting data from this study in a similar timeframe as the SEISMiC Extension Study.

“The SEISMiC Extension Study builds upon the positive data from our three Phase 2 studies in acute heart failure and early cardiogenic shock and is expected to determine the best dosing regimen for our anticipated Phase 3 program in cardiogenic shock,” said Craig Fraser, Windtree's President and Chief Executive Officer. “Along with data from more severe, SCAI Stage C cardiogenic shock patients coming from a parallel study, program results in mid-2024 are expected to contribute to finalizing our strategy and design for Phase 3 clinical trials and our end of Phase 2 discussions with FDA.”

About Istaroxime
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock and acute decompensated heart failure. Windtree’s heart failure platform includes follow-on pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

[Monksdream]

WINT new 52 week low

[Mr. Zen]

Windtree is actively seeking opportunities to enter into one or more strategic alliances or other strategic transactions that would support development activities for istaroxime, and the SERCA2a activators to gain regulatory and commercial market expertise as well as financial resources. For rostafuroxin, we are currently seeking an out-licensing partner.”

As a company, Windtree is open to exploring additional mergers and/or acquisitions that would complement Windtree’s areas of focus or broaden Windtree’s potential to grow its business and potentially enhance its market value for stockholders and increase our capabilities to bring important new therapies to patients in need.

Inquiries for business development should be sent to [e-mail]

[Mr. Zen]

https://sih-st-charts.stocktwits-cdn.com/production/original_552076783.jpg

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the European Patent Office has granted Patent No. 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates. The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline. The pure SERCA2a Activators are devoid of action on the Na+/K+ pump while activating SERCA2a. The new European patent, titled: “ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF Heart Failure,” provides patent protection until October 9, 2039 for the family of compounds with the pure SERCA2a mechanism of action. The other family of SERCA2a Activators is the dual mechanism of action (inhibition of the Na+/K+ pump and activation of SERCA2a) which the Company previously announced had received composition of matter patents from the European Patent Office and the U.S. Patent and Trademark Office.

The pure SERCA2a Activators have SERCA2a stimulatory activity, are intended to have oral and intravenous administration and would potentially be developed for use in the chronic out-patient heart failure market as well as the acute setting. In the U.S., approximately 6 million people (nearly 2% of the adult population) have heart failure and approximately half of these patients are expected to die within five years of diagnosis; and in the combined U.S., EU and Japan markets, there are more than 18 million patients suffering from heart failure. Heart failure is the leading cause of hospitalization in patients aged 65 years and older.

“SERCA2a activity is decreased in heart failure. Windtree believes activation of SERCA2a represents a potentially important advancement in heart failure treatment for patients,” said Craig Fraser, CEO of Windtree Therapeutics. “Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart’s main pumping chamber (left ventricle) becomes stiff and unable to fill properly. SERCA2a activation has the potential to be beneficial in this type of heart failure that accounts for nearly one-half of the chronic heart failure patients. Given the potential for oral (tablet) use, it could be utilized in both the chronic out-patient and hospital markets.”

About Pure SERCA2a Activators
These compounds activate SERCA2a without activity on the Na+/K+ pump. Windtree Therapeutic’s research program is evaluating these preclinical product candidates in heart failure.

About Dual Mechanism SERCA2a Activators
Dual Mechanism SERCA2a Activators activate SERCA2a and inhibit the Na+/K+ pump. Windtree Therapeutic’s research program is evaluating these preclinical product candidates in heart failure.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s pre-clinical heart failure platform includes follow-on, potentially oral, SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

[Mr. Zen]

10-K out ..... As of November 9, 2023, there were 5,148,219 shares of the registrant’s common stock outstanding, par value $0.001 per share.

[Mr. Zen]

Windtree to Present at the Sidoti Micro Cap Conference on November 16th
November 08 2023 - 08:00AM
GlobeNewswire Inc.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate update at the Sidoti Micro Cap Conference on Thursday, November 16, 2023 at 1:45pm ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event on November 15 and 16.

The corporate update presentation can be viewed live by clicking on this link https://sidoti.zoom.us/webinar/register/WN_roHsRn17R5m0wQo8wOIKsQ or a recorded webcast may be accessed from the Events section of Windtree’s website at https://ir.windtreetx.com/events.

[Mr. Zen]

krll123
12:01 PM
$WINT To all new investors
I am a cardiologist that has done over 2 weeks of research reading all thetrial data
Read all my posts but draw your own conclusions I own 300k shares

https://stocktwits.com/krll123/message/549609340

[stock1ace1]

Wint $1.30

[big bambino]

3 conferences in 1 week. That must be a record. Kickoff starts today 12th then 17th & 19th. lets see what comes of them.

[Mr. Zen]

Windtree to Present at the ThinkEquity Conference on October 19th in New York City
October 12 2023 - 07:30AM
GlobeNewswire Inc.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET. Windtree management will also be hosting 1x1 meetings with investors at the event.

The presentation will provide clinical development and business updates, including the Company’s progress on its lead product candidate istaroxime in cardiogenic shock.

Click here to register and attend the event: Click here.

About Istaroxime
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock and acute decompensated heart failure. Windtree’s heart failure platform includes follow-on pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:

Matt Epstein
[e-mail]

[TIMGZ]

MIGHT BE NEXT "WINT"
WE SHALL SEE

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be participating in a panel discussion titled, “Cardiac Kids: Late-Stage Advancement for Cardiovascular Disorders,” at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023 at 10:30am ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event.

The panel discussion will include Windtree’s progress on its lead pipeline candidate istaroxime for the treatment of cardiogenic shock. The panel can be accessed on the Company’s corporate website at: Events | Windtree Therapeutics, Inc (windtreetx.com).

About Istaroxime
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock and acute decompensated heart failure. Windtree’s heart failure platform includes follow-on pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:

Matt Epstein
[e-mail]

[Mr. Zen]

After Hours gapper WINT

Windtree Therapeutics Inc $1.30 $0.29 (27.10%)

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.

The presentation will provide clinical development and business updates including Windtree’s progress on its lead product candidate istaroxime in cardiogenic shock.

Click here to register and attend the event: Click here

About Istaroxime
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

[Mr. Zen]

Form 4 again, another 2500 direct purchase by CEO, wonder if he knows when his company is undervalued?????

[Mr. Zen]

Form 4... CEO added to his pile....2,500 A $0.9 55,377 D

[Monksdream]

WINT new 52 week low

[Monksdream]

WINT new 52 week low

[Stockexpertpro]

This was from 5 Months ago should have Phase 2 Study update Soon on Billion Dollar Drug They was going to study it at 60 hours of use on 30 patienes Should have News Coming Low Float Bio Tech trading under cash Think they captured the float like a month or 2 ago look Close at the Chart Huge Volume Back in June someone bought the entire Float

https://schrts.co/CzEZSvbw

https://ir.windtreetx.com/events



Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

https://finance.yahoo.com/news/windtree-therapeutics-nasdaq-wint-developing-130000361.html

Should have News Coming i think we will get news soon

Look at the Volume in June it was the entire Shares outstanding bought at much higher prices

[Stockexpertpro]

This was from 5 Months ago should have Phase 2 Study update Soon on Billion Dollar Drug They was going to study it at 60 hours of use on 30 patienes Should have News Coming Low Float Bio Tech trading under cash Think they captured the float like a month or 2 ago look Close at the Chart Huge Volume Back in June someone bought the entire Float

https://schrts.co/CzEZSvbw

https://ir.windtreetx.com/events



Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

https://finance.yahoo.com/news/windtree-therapeutics-nasdaq-wint-developing-130000361.html

Should have News Coming i think we will get news soon

Look at the Volume in June it was the entire Shares outstanding bought at much higher prices

[Mr. Zen]

Appointment of Principal Accounting Officer

(c) Effective August 24, 2023, the Board of Directors (the “Board”) of Windtree Therapeutics, Inc. (the “Company”) appointed Jamie McAndrew as Vice President, Controller & Chief Accounting Officer. Ms. McAndrew will also act as the Company’s principal accounting officer.

Ms. McAndrew, age 43, joined the Company in November 2013 and served in various finance roles of increasing responsibility, most recently as Executive Director, Corporate Controller. Previously, Ms. McAndrew held roles of increasing responsibility at KPMG LLP from January 2008 to October 2013, at which time she served as a Manager in Transaction Services. Ms. McAndrew is a certified public accountant (currently inactive status) and received her B.A. in Philosophy and Political Science from Villanova University and her Master of Professional Accountancy from the J. Mack Robinson College of Business at Georgia State University.

In connection with Ms. McAndrew’s appointment as Vice President, Controller & Chief Accounting Officer, she will receive an annual base salary of $301,000 and an annual target bonus of 30% of her base salary.

[Monksdream]

WINT new 52 week low

[Mr. Zen]

FORM 4 CEO just bought 45,867 on the open market

[Mr. Zen]

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,730,746 covering the Company’s dual mechanism SERCA2a Activators. The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.

The newly issued patent follows the Company’s announcement in April 2023 that the European Patent Office granted Patent No. 3599243, which also provides patent coverage for the dual mechanism SERCA2a Activator class of drug candidates. Windtree has preclinical drug candidates with dual mechanisms of action (inhibition of the Na+/K+ pump and activation of SERCA2a) as well as pure SERCA2a activators (devoid of action on the Na+/K+ pump).

SERCA2a has been known to play a key role in heart failure and has thus been a much sought after but elusive target for several potential drug therapies. Istaroxime and these follow-on SERCA2a Activators look to deliver on the potential of SERCA2a activation in heart failure. The dual mechanism compounds activate SERCA2a and inhibit the Na+/K+ pump in a manner similar to istaroxime, which is administered intravenously (IV) and is the Company’s lead program for cardiogenic shock and acute decompensated heart failure. These new dual mechanism SERCA2a Activator product candidates are intended to be both oral and IV therapies, which could result in a hospital inpatient therapy for acute decompensated heart failure as well as an outpatient oral therapy for hospital discharge and chronic heart failure treatment.

“We are making steady progress with our IP portfolio strategy for the dual mechanism SERCA2a Activator family of drug candidates,” said Craig Fraser, Chief Executive Officer of Windtree Therapeutics. “We plan to position these new compounds as a ‘fast follow-on’ to istaroxime while offering the potential of oral bioavailability for use as a treatment for chronic heart failure. Much may be accomplished for heart failure patient treatment with this innovation.”

About Dual Mechanism SERCA2a Activators
Dual Mechanism SERCA2a Activators activate SERCA2a and inhibit the Na+/K+ pump. Windtree Therapeutic’s research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a Activator heart failure compounds.

About Istaroxime
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock and acute decompensated heart failure. Windtree’s heart failure platform includes follow-on pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

[Awl416]

Stop messaging me via this ticker

Thanks

[stock1ace1]

$1.38s filled !! Fire sale thanks mms

[stock1ace1]

Huge spread bids in !!

[stock1ace1]

Floats getting accumulated

[stock1ace1]

Slight pullback for next leg up

[Mr. Zen]

Today's Volume 76.7KBelow Avg.

and a selloff, what does this company have to do to gain some respect? Maybe start selling AI Hoes.

[stock1ace1]

News -> Windtree Therapeutics Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

9:05a ET 8/16/2023 - Benzinga

[stock1ace1]

Sellers drying up

[surf1944]

WINT should move to $1.95 the recent high and then to the big open gap from $2.50 to $5.50

[stock1ace1]

Squeeze time $1.57 !!!

[stock1ace1]

Hod break watching for the whales to show up

[glens0]

https://tickeron.com/ticker/WINT/?utm_source=stocktwits_free&utm_medium=news&utm_campaign=TICKER_SUMMARY&utm_term=Stock_78062_WINT&utm_content=15953643

[glens0]

Post from another board, ($WINT the meeting tomorrow hopefully will give us some clues to where the ship is sailing)

[stock1ace1]

5 mill o/s dont think shorts are going to win much longer open gap to fill way above $4.00+

[Mr. Zen]

The chart says liftoff, lets see if the shorts battle it back down

[glens0]

Got more shares just before close A/H